BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 31410185)

  • 1. Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving
    Kessel K; Seifert R; Schäfers M; Weckesser M; Schlack K; Boegemann M; Rahbar K
    Theranostics; 2019; 9(17):4841-4848. PubMed ID: 31410185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
    Rahbar K; Boegemann M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):12-19. PubMed ID: 29026946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of short-term dexamethasone on the efficacy of
    Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM
    Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes of
    Barber TW; Singh A; Kulkarni HR; Niepsch K; Billah B; Baum RP
    J Nucl Med; 2019 Jul; 60(7):955-962. PubMed ID: 30683770
    [No Abstract]   [Full Text] [Related]  

  • 5. [
    Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID;
    Lancet Oncol; 2024 May; 25(5):563-571. PubMed ID: 38621400
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Karimzadeh A; Heck M; Tauber R; Knorr K; Haller B; D'Alessandria C; Weber WA; Eiber M; Rauscher I
    J Nucl Med; 2023 Mar; 64(3):402-409. PubMed ID: 36137758
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Bräuer A; Grubert LS; Roll W; Schrader AJ; Schäfers M; Bögemann M; Rahbar K
    Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1663-1670. PubMed ID: 28624848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
    Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
    J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of
    Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
    Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
    Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
    Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of
    Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS
    J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic efficacy, prognostic variables and clinical outcome of
    Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
    Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TheraP: a randomized phase 2 trial of
    Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
    BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of [
    Tauber R; Knorr K; Retz M; Rauscher I; Grigorascu S; Hansen K; D'Alessandria C; Wester HJ; Gschwend J; Weber W; Eiber M; Langbein T
    J Nucl Med; 2023 Aug; 64(8):1244-1251. PubMed ID: 37321824
    [No Abstract]   [Full Text] [Related]  

  • 15. Prediction of response and survival after standardized treatment with 7400 MBq
    Rasul S; Hartenbach M; Wollenweber T; Kretschmer-Chott E; Grubmüller B; Kramer G; Shariat S; Wadsak W; Mitterhauser M; Pichler V; Vraka C; Hacker M; Haug AR
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1650-1657. PubMed ID: 33128131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [
    Ahmadzadehfar H; Wegen S; Yordanova A; Fimmers R; Kürpig S; Eppard E; Wei X; Schlenkhoff C; Hauser S; Essler M
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1448-1454. PubMed ID: 28488028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [
    Ahmadzadehfar H; Rahbar K; Baum RP; Seifert R; Kessel K; Bögemann M; Kulkarni HR; Zhang J; Gerke C; Fimmers R; Kratochwil C; Rathke H; Ilhan H; Maffey-Steffan J; Sathekge M; Kabasakal L; Garcia-Perez FO; Kairemo K; Maharaj M; Paez D; Virgolini I
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):113-122. PubMed ID: 32383093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined
    Suman S; Parghane RV; Joshi A; Prabhash K; Talole S; Basu S
    Prostate; 2021 Nov; 81(15):1225-1234. PubMed ID: 34469602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
    Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
    Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
    Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.